(Press-News.org) Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a study in the November 17 issue of JAMA.
"Hepatocellular [liver] carcinoma (HCC) is the sixth most common malignancy worldwide, with approximately 600,000 new cases per year. Patients with inoperable or metastatic disease have a median [midpoint] survival of only a few months. Despite the lack of a clear survival benefit, doxorubicin has become a routinely and widely used agent in the treatment of HCC," according to background information in the article. Sorafenib has shown a statistically significant increase in median overall survival compared to placebo. A phase 1 study assessing the feasibility and tolerability of sorafenib in combination with doxorubicin for patients with solid tumors has shown promise. The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial.
Ghassan K. Abou-Alfa, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a randomized, phase 2 study of doxorubicin plus sorafenib and doxorubicin plus placebo in patients with advanced HCC. The study, conducted from April 2005 to October 2006, included 96 patients (76 percent male; median age, 65 years) who were randomly assigned to receive doxorubicin intravenously every 21 days plus either sorafenib or placebo orally twice a day. The date of the last patient's follow-up was April 2008.
Following complete accrual, an unplanned early analysis for efficacy was performed by the independent data monitoring committee, so the trial was halted. The 2 patients remaining in the placebo group at that time were offered sorafenib.
There were 51 total time-to-disease progression events (24, doxorubicin plus sorafenib vs. 27, doxorubicin plus placebo). Time to disease progression was a median of 6.4 months for patients who received doxorubicin plus sorafenib and 2.8 months for those who received doxorubicin plus placebo.
Sixty-three patients died during the course of the study: 25 in the doxorubicin-sorafenib group; 38 in the doxorubicin-placebo group. Median overall survival was 13.7 months among patients treated with doxorubicin plus sorafenib vs. 6.5 months among those who received doxorubicin plus placebo. Analysis indicated a 51 percent reduction in the risk of death in patients treated with doxorubicin and sorafenib vs. doxorubicin and placebo.
The number of total progression-free survival events was 70, including 32 in the doxorubicin-sorafenib group and 38 in the doxorubicin-placebo group, with the median progression-free survival being 6 months among patients treated with doxorubicin plus sorafenib vs. 2.7 months among those who received doxorubicin plus placebo. Analysis showed a 46 percent reduction in the risk of progression or death among patients treated with doxorubicin plus sorafenib vs. doxorubicin plus placebo.
Toxicity profiles were similar to those for the single agents.
"In summary, among patients with advanced HCC, treatment with sorafenib doxorubicin compared with doxorubicin plus placebo resulted in greater median time to progression, overall survival, and progression-free survival. The degree to which this improvement may represent synergism between sorafenib and doxorubicin remains to be defined. This trial has served as the basis for the ongoing phase 3 trial of sorafenib plus doxorubicin vs. sorafenib alone," the authors conclude.
INFORMATION:
(JAMA. 2010;304[19]:2154-2160. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Research from a six year study on migrating geese has discovered an interesting outcome – they return to the same spots they were taken to as youngsters.
The findings of the study, published online today [November 17] in the journal Molecular Ecology, suggest young light-bellied Brent geese learn their migratory destinations from parents.
This means their routes are learned through culture rather than inherited genetically, raising some interesting questions about why this species of goose demonstrates this behaviour.
Xavier Harrison, from the Centre for Ecology & ...
Heart imaging specialists at Johns Hopkins have shown that a combination of CT scans that measure how much blood is flowing through the heart and the amount of plaque in surrounding arteries are just as good as tests that are less safe, more complex and more time-consuming to detect coronary artery disease and its severity.
"Our findings should reassure cardiologists and patients that the newer, state-of-the-art CT scans are just as good as established older technologies in diagnosing the presence and severity of coronary artery disease," says cardiologist and lead study ...
Rolling back suggestions from previous studies, a Johns Hopkins study of 950 healthy men and women has shown that taking daily doses of a cholesterol-lowering statin medication to protect coronary arteries and ward off heart attack or stroke may not be needed for everyone.
In a study to be presented Nov. 16 at the American Heart Association's (AHA) annual Scientific Sessions in Chicago, the Johns Hopkins team found that nearly 95 percent of all heart attacks, strokes or heart-related deaths occurred in the half of study participants with some measureable buildup of artery-hardening ...
WASHINGTON, D.C.—U.S. policymakers must focus more closely on developing new energy storage technologies as they consider a national renewable electricity standard, according to one of the principal recommendations in a newly released report, Integrating Renewable Electricity on the Grid, by the American Physical Society's Panel on Public Affairs (POPA). Establishing a national renewable electricity standard will help to unify the fragmented U.S. grid system—an important step in the wider adoption of using more wind and solar for energy generation.
But, without the focus ...
The types of gut bacteria that populate the guts of primates depend on the species of the host as well as where the host lives and what they eat. A study led by Howard Ochman at Yale University examines the gut microbial communities in great apes, showing that a host's species, rather than their diet, has the greatest effect on gut bacteria diversity. These findings will publish next week in the online, open access journal PLoS Biology.
"Bacteria are crucial to human health. They enhance the immune system, protect against toxins, and assist in the maturation and renewal ...
Keeping in close contact with heart failure patients once they leave the hospital has been an ongoing challenge for physicians. A patient's condition can worsen with no notice and early intervention could potentially make a big difference.
Researchers at Yale School of Medicine thought they found the solution with a telephone call-in program designed to improve doctor-patient communication. But results from their study published in the November 16 New England Journal of Medicine shows that this program failed to improve patient outcomes. The paper will be presented simultaneously ...
The nine-month pregnancy in humans is influenced by the structure of the placenta, according to new research into the evolution of reproduction in mammals which ends a 100-year mystery.
The study, by Durham and Reading universities, shows that babies grow twice as fast in the wombs of some mammals compared to others. The difference in growth rates appears to be due to the structure of the placenta and the way it connects mother and baby.
The research has found that the more intimate the connection is between the tissues of the mother and the foetus, the faster the ...
A key enzyme in Mycobacterium tuberculosis that enables the microbe to reproduce rapidly could be a golden target for new drugs against tuberculosis (TB), according to a study published in Microbiology on 17 November.
The human equivalent of this enzyme has been targeted in some cancer treatments as well as in immunosuppressive chemotherapies. Scientists at the University of Birmingham have now shown that inhibiting the same enzyme in M. tuberculosis effectively kills the bacterial cells.
The enzyme called IMPDH is crucial for the survival of both human and bacterial ...
Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.
Scientists in the USA have studied 20 genes that are targeted by existing therapies and found that there are significant changes to these genes in a broad range of patients' tumours, including many for which these drugs are not being used at present. ...
Researchers have shown that point mutations – mis-spellings in a single letter of genetic code – that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.
Using mass spectrometry for identifying the genetic make-up of cancer cells, OncoMap can determine the point ...
